00:47 , Jul 27, 2018 |  BC Innovations  |  Product R&D

Syncona’s sister act

With the final pieces of its gene therapy portfolio in place, Syncona Investment Management Ltd. thinks its five “sister companies” are poised to capitalize on recent regulatory and technological advances in gene therapy, and push...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
08:00 , Mar 3, 2008 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Arthrogen B.V. Amsterdam, the Netherlands Technology: Inducible adeno-associated virus (AAV) vector technology Disease focus: Autoimmune Clinical status: Preclinical Founded: 2005 by the Academic Medical Center and the Dubai Bone & Joint Center University collaborators: Academic...
08:00 , Mar 3, 2008 |  BioCentury  |  Emerging Company Profile

Arthrogen: Expression on demand

Though the list of failures in gene therapy is long, Arthrogen B.V. believes its adeno-associated virus vector is safer and capable of more efficient expression than vectors used by other companies. Through a deal with...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Company News

Arthrogen BV, Galapagos NV deal

Arthrogen and GLPG's BioFocus division (Saffron Walden, U.K.) partnered to identify gene therapy targets for rheumatoid arthritis (RA). Under the three-year deal, BioFocus will develop assays to screen its SilenceSelect collection of gene sequences. BioFocus...
07:00 , May 27, 1997 |  BC Week In Review  |  Company News

Chondrex LLC, Stratagene deal

Stratagene received exclusive rights in North America and Europe to distribute Chondrex's Arthrogen-CIA arthritogenic monoclonal antibodies that induce collagen arthritis in animal models. Chondrex said the MAbs can induce disease in one week, compared to...